Mayo Clinic prepared to commenced phase II FDA clinical trial for treatment of COVID-19 with Vicromax
On Apr. 16, 2020, BioSig Technologies announced that its subsidiary ViralClear Pharmaceuticals, had updated its clinical development program for Vicromaxﾙ (merimepodib, or MMPD) as a treatment for COVID-19.
Under the terms of a new agreement, the Phase II clinical trial wasconducted at Mayo Clinic. The study was a randomized, placebo-controlled trial. Data from the Phase II trial was expected within three months.
Tags:
Source: GlobalNewswire
Credit:
